Söndag 22 December | 02:10:13 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-11-18 13:30 Kvartalsrapport 2025-Q3
2025-08-26 13:30 Kvartalsrapport 2025-Q2
2025-05-27 N/A Årsstämma
2025-05-20 13:30 Kvartalsrapport 2025-Q1
2025-02-27 08:30 Bokslutskommuniké 2024
2024-11-18 - Kvartalsrapport 2024-Q3
2024-11-12 - Extra Bolagsstämma 2024
2024-08-26 - Kvartalsrapport 2024-Q2
2024-05-31 - X-dag ordinarie utdelning MONI 0.00 SEK
2024-05-30 - Årsstämma
2024-05-16 - Kvartalsrapport 2024-Q1
2024-02-29 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-09 - Kvartalsrapport 2023-Q2
2023-05-31 - X-dag ordinarie utdelning MONI 0.00 SEK
2023-05-30 - Årsstämma
2023-05-09 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-07 - Kvartalsrapport 2022-Q3
2022-11-01 - Extra Bolagsstämma 2022
2022-08-26 - Kvartalsrapport 2022-Q2
2022-05-18 - Kvartalsrapport 2022-Q1
2022-05-09 - X-dag ordinarie utdelning MONI 0.00 SEK
2022-02-21 - Bokslutskommuniké 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-18 - Kvartalsrapport 2021-Q1
2021-05-04 - X-dag ordinarie utdelning MONI 0.00 SEK
2021-02-15 - Bokslutskommuniké 2020
2020-11-17 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-05-20 - X-dag ordinarie utdelning MONI 0.00 SEK
2020-05-19 - Årsstämma
2020-05-18 - Kvartalsrapport 2020-Q1
2020-02-25 - Bokslutskommuniké 2019

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Monivent är verksamt inom medicinteknik. Bolaget är specialiserat inom utvecklingen av medicintekniska produkter. Produkterna vidaresäljs under varierade varumärken och är anpassade för klinisk användning vid förlossnings- och neonatalavdelningar. Produktportföljen är bred och består huvudsakligen av mjukvara och monitorer, laddningsstationer samt sensormoduler. Utöver erbjuds även produkter för utbildning och simuleringsträning. Störst närvaro återfinns inom den europeiska marknaden.
2024-02-09 09:30:00

The International Liaison Committee on Resuscitation (ILCOR) has recommended improvements in training for neonatal resuscitation, highlighting the potential role of respiratory function monitors (RFMs). A recent study concluded that standardized training with a simple interface RFM (Neo Training) led to a significant reduction in mask leakage and improvement in all other ventilation parameters. The study has been led by Dr Caitriona M Ni Chathasaigh, The National Maternity Hospital, Dublin and involves a large group of healthcare professionals in maternity and neonatal services.

The study "Newborn face mask ventilation training using a standardized intervention and respiratory function monitor: a before and after manikin study" was conducted with 412 users in 13 hospitals in Ireland. The aim was to evaluate whether a standardized manikin training using an RFM with simple interface could reduce mask leakage during ventilation. To date, the visual feedback from RFMs has required considerable instruction, time and experience to interpret. The need for improved training on RFM interpretation was emphasized among resuscitators involved in a previous trial, suggesting that a simpler visual interface may facilitate interpretation.

The conclusion of the study, presented in the Archive in Disease in Childhood, Fetal and Neonatal edition, was that the simplicity of Neo Training's color-coded visual display, which uses a traffic light system to depict the expiratory tidal volume, requires minimal training to interpret the feedback, as demonstrated by the short training time. The results from the study were that leak before training was 31% (10-69%) compared to 10% (6-18%) after training. Improvements were also noted for all other ventilation parameters.

"Previous studies have shown that the RFMs available for training and research have been far too complex and presented feedback in a way that was difficult to interpret. This extensive study from Ireland emphasizes the ease of use and simplicity that are essential in Monivent's products and which we have put a lot of effort and care into during development", says Karin Dahllöf, CEO of Monivent.